Pandemic Pricing: The Risks and Rewards of Fast-Tracking Value-Based Drug Evaluations

Matthew Sussman, BHE's VP of Modeling & Strategy Services, discusses the use of remdesivir for COVID-19 patients and the risks and rewards of fast tracking value-based drug evaluations.

Matt Sussman, VP of Modeling & Strategy at Panalgo, discusses the risks and rewards of fast-tracking drug price evaluations in the COVID era in this Pharmacy Times article. He notes that ICER’s expedited evaluation of remdesivir raises some questions related to value-based pricing evaluations that shouldn’t be overlooked. Read the full article for Sussman’s view on the risks of rushing and the rewards of readiness when it comes to value-based pricing in the COVID era.

Click here to read the full article.